



November 8, 2013

New Data Highlighting Foundation Medicine's Second Clinical Product to be Presented at American Society of Hematology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ: FMI) today announced that new clinical data highlighting the company's second clinical product, a fully informative genomic profile for hematologic malignancies being developed in collaboration with Memorial Sloan-Kettering Cancer Center, will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 7-10, 2013 at the Ernest N. Morial Convention Center in New Orleans.

"We are making progress toward the introduction of our second clinical product, FoundationOne™ Heme, by early 2014 and look forward to sharing initial data with the hematology community at this year's ASH meeting," stated Vincent Miller, M.D., chief medical officer of Foundation Medicine. "We are building on our comprehensive next-generation sequencing platform to offer a fully informative genomic profile with clinically actionable information for oncologists and patients with hematologic malignancies. We believe these findings will advance patient care for blood based cancers."

The schedule for oral presentations by Foundation Medicine and its collaborators is as follows:

Date & Time: Monday, December 9, 2013 at 7:15 a.m. CT

Title: Identification of Actionable Genomic Alterations in Hematologic Malignancies by a Clinical Next Generation Sequencing-Based Assay

Abstract number: 230

Session: 611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Genomic Alterations in Acute Lymphoblastic Leukemia--Implications for Pathogenesis, Prognosis and Therapy

Type: Oral Presentation

Location: Room 291-292

Collaborator: Memorial Sloan-Kettering Cancer Center

Date & Time: Monday, December 9, 2013 at 3:15 p.m. CT

Title: Overview of The Genomic Landscape of High Risk Diffuse Large B-Cell Lymphoma Using Targeted DNA and RNA Sequencing

Abstract number: 501

Session: 622. Non-Hodgkin Lymphoma: Biology, Excluding Therapy: Genomics

Type: Oral Presentation

Location: Room 217-219

Collaborator: Hackensack University Medical Center

Date & Time: Monday, December 9, 2013 at 7:15 p.m. CT

Title: Pilot Study to Evaluate The Prevalence of Actionable Oncogenic Mutations in Patients with Relapsed Refractory Multiple Myeloma

Abstract number: 755

Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Microenvironment

Type: Oral Presentation

Location: Room 388-390

Collaborator: Memorial Sloan-Kettering Cancer Center

The schedule for poster presentations by Foundation Medicine and its collaborators is as follows:

Date & Time: Saturday, December 7, 2013 from 5:30 to 7:30 p.m. CT

Title: Patient Derived Xenograft (PDX) Models Faithfully Recapitulated The Genetic Composition of Primary AML

Abstract number: 1328

Session: 611. Leukemias: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I

Type: Poster Session

Location: Hall E

Collaborator: Memorial Sloan-Kettering Cancer Center

Date & Time: Saturday, December 7, 2013 from 5:30 to 7:30 p.m. CT

Title: Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms

Abstract number: 1588
Session: 634. Myeloproliferative Syndromes: Clinical: Poster I
Type: Poster Session
Location: Hall E
Collaborator: Memorial Sloan-Kettering Cancer Center

Date & Time: Saturday, December 7, 2013 from 5:30 to 7:30 p.m. CT
Title: Profiling Genomic Alterations of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform
Abstract number: 1761
Session: 622. Non-Hodgkin Lymphoma: Biology, Excluding Therapy: Poster I
Type: Poster Session
Location: Hall G
Collaborator: Memorial Sloan-Kettering Cancer Center

Date & Time: Saturday, December 7, 2013 from 5:30 to 7:30 p.m. CT
Title: Mutational Profiling of Myeloid Malignancies for Prediction of Disease Relapse Following Allogeneic Stem Cell Transplantation
Abstract number: 2096
Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Poster I
Type: Poster Session
Location: Hall G
Collaborator: Memorial Sloan-Kettering Cancer Center

Date & Time: Sunday, December 8, 2013 from 6:30 to 8:30 p.m. CT
Title: Comprehensive Mutational Profiling in Myelodysplastic Syndromes Treated with Decitabine and Tretenoin
Abstract number: 2791
Session: 633. Myelodysplastic Syndromes: Poster II
Type: Poster Session
Location: Hall E
Collaborator: Memorial Sloan-Kettering Cancer Center

Date & Time: Sunday, December 8, 2013 from 6:30 to 8:30 p.m. CT
Title: Extensive High-Depth Sequencing of Longitudinal CLL Samples Identifies Frequent Mutations in MAP Kinase Signaling and Novel Mutations Activating Notch and Beta-Catenin
Abstract number: 2858
Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster II
Type: Poster Session
Location: Hall E
Collaborator: Memorial Sloan-Kettering Cancer Center

Date & Time: Monday, December 9, 2013 from 6:00 to 8:00 p.m. CT
Title: High-Throughput Mutational Profiling Of Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia Reveals Frequent Mutations In NRAS In JAK2V617F-Negative Post-MPN AML
Abstract number: 4098
Session: 635. Myeloproliferative Syndromes: Basic Science: Poster III
Type: Poster Session
Location: Hall E
Collaborator: Memorial Sloan-Kettering Cancer Center

About Foundation Medicine

Foundation Medicine® (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's initial clinical assay, FoundationOne™, is a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® is a registered trademark, and FoundationOne™ is a trademark, of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits to patients of next-generation sequencing of their tumors and blood based cancers, clinical data related to Foundation Medicine's products, Foundation Medicine's plans or ability to develop and commercialize new products, including the commercial launch of FoundationOne™ Heme, and Foundation Medicine's participation in the ASH annual meeting. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that FoundationOne™, FoundationOne™ Heme and any subsequent products may never achieve significant commercial adoption or reimbursement support; Foundation Medicine is unable to achieve profitability, to compete successfully, to manage its growth, or to develop its molecular information platform; and the risks described under the caption "Risk Factors" in Foundation Medicine's Registration Statement on Form S-1 (File No. 333-190226), which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.

Media Contact:

Pure Communications, Inc.
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com

or

Investor Contact:

Matt Clawson, 617-418-2283
ir@foundationmedicine.com

Source: Foundation Medicine, Inc.

News Provided by Acquire Media